CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-17 | Mercier Johanna Director | Option exercise · Restricted Stock Unit | −2,100 | 0 | ||
| 2024-05-15 | ABERNETHY MATT Chief Financial Officer | Option exercise 10b5-1 | +15,000 | $73.60 | $1.1M | 46,528 |
| 2024-05-15 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −15,000 | $140.24 | $2.1M | 31,528 |
| 2024-05-15 | ABERNETHY MATT Chief Financial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −15,000 | $73.60 | $1.1M | 15,000 |
| 2024-05-14 | LYONS GARY A Director | Option exercise 10b5-1 | +12,500 | $42.76 | $535K | 129,447 |
| 2024-05-14 | LYONS GARY A Director | Sale 10b5-1 | −12,500 | $135.63 | $1.7M | 116,947 |
| 2024-05-14 | LYONS GARY A Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −12,500 | $42.76 | $535K | 12,500 |
| 2024-05-14 | ABERNETHY MATT Chief Financial Officer | Option exercise 10b5-1 | +15,000 | $73.60 | $1.1M | 46,528 |
| 2024-05-14 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −15,000 | $135.66 | $2.0M | 31,528 |
| 2024-05-14 | ABERNETHY MATT Chief Financial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −15,000 | $73.60 | $1.1M | 30,000 |
| 2024-05-06 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +273 | $79.02 | $22K | 7,780 |
| 2024-05-06 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −273 | $140.55 | $38K | 7,507 |
| 2024-05-06 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −273 | $79.02 | $22K | 4,899 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 | +7,231 | $81.49 | $589K | 48,009 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −7,231 | $133.36 | $964K | 40,778 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 | +12,587 | $81.05 | $1.0M | 53,365 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −12,587 | $133.36 | $1.7M | 40,778 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −7,231 | $81.49 | $589K | 26,292 |
| 2024-04-15 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −12,587 | $81.05 | $1.0M | 0 |
| 2024-04-01 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +272 | $79.02 | $21K | 7,779 |
Page 33 of 49 · 963 trades